| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK | /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC | 01 Jul 2025 | 0001055951 |
| OrbiMed Capital GP V LLC | Director, 10%+ Owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK | /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC | 01 Jul 2025 | 0001615374 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRVS | Common Stock | Exercise of in-the-money or at-the-money derivative security | $4,891,894 | +1,397,684 | +20% | $3.50 | 8,341,338 | 27 Jun 2025 | See Footnotes | F2, F3 |
| transaction | CRVS | Common Stock | Sale | $4,891,894 | -1,176,332 | -14% | $4.16 | 7,165,006 | 27 Jun 2025 | See Footnotes | F1, F2, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRVS | Common Warrants (right to buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -1,397,684 | -100% | $0.000000 | 0 | 27 Jun 2025 | Common Stock | 1,397,684 | $3.50 | See Footnotes | F2, F3 |
| Id | Content |
|---|---|
| F1 | On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares. |
| F2 | These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. |
| F3 | This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. |